



## This week in therapeutics

| Indication                         | Target/marker/pathway           | Summary  | Licensing status  | Publication and contact information  |
|------------------------------------|---------------------------------|--|---|--|
| Cardiovascular disease             |                                 |  |   |  |
| Ischemia/<br>reperfusion<br>injury | Glutathione peroxidase 4 (GPX4) | Mouse studies suggest inhibiting ferroptosis could help treat ischemia/reperfusion injury in the liver and kidney. The GPX4 enzyme decreases toxic phospholipid hydroperoxides associated with ferroptosis, an apoptosis- and necrosis-independent form of cell death. In a mouse model of hepatic ischemia/reperfusion injury, the spiroquinoxalinamine liproxstatin-1 decreased markers of phospholipid hydroperoxidation and hepatic tissue injury compared with vehicle. Next steps include improving the physicochemical and <i>in vivo</i> properties of liproxstatin-1 and evaluating the compound in indications related to ischemia/reperfusion injury. | Patent application<br>filed; available for<br>licensing | Friedmann Angeli, J.P. et al. Nat. Cell Biol.; published online Nov. 17, 2014; doi:10.1038/ncb3064  Contact: Marcus Conrad, German Research Center for Environmental Health, Neuherberg, Germany e-mail: marcus.conrad@helmholtz-muenchen.de |
|                                    |                                 | SciBX 7(48); doi:10.1038/scibx.2014.1409<br>Published online Dec. 18, 2014   |   |  |